Circulating stem cells of different origin have been demonstrated to improve repair of various organs both after systemic and local application, although the mechanisms that cause these effects are still not fully understood. We have used a combination of DNA microarray analysis and in vitro migration assays to screen for molecules that mediate homing of long-term renewing adult bone marrow-derived multipotent mesenchymal stem cells (BM-MASCs). We show that the cytokine receptor CCR2 is necessary for organ-specific homing of bone marrow-derived MASCs to the heart in a transgenic mouse model and into hearts damaged by ischemia/reperfusion. Homing and migration of stem cells was dependent on the intracellular adaptor molecule FROUNT, which interacts with CCR2. FROUNT was required for polarization of MASCs, resulting in clustering of CCR2 and reorganization of the cytoskeleton. Recruited MASCs summoned by the CCR2 ligand MCP-1/ CCL2 expressed SDF1, which might trap additional bone marrow-derived circulating cells to contribute to the complex process of homing and retention of circulating stem and progenitor cells to remodel diseased organs.
INTRODUCTION
Cell therapy currently attracts growing interest as a new approach to treat diseases of the heart, including heart failure. Several different types of stem/progenitor cells have been used in various preclinical and clinical trials. In particular, bone marrow-derived multipotent adult mesenchymal stem cells (BM-MASCs), mesenchymal stem cells (MSCs), and endothelial precursor cells (EPCs), which possess a certain degree of multipotency, have attracted attention as therapeutic tools since they can be obtained with relative ease and expanded in culture (Dimmeler et al., 2005) . So far, most studies both in animals and in humans reported encouraging results in respect to post myocardial infarction remodeling and ventricular performance. Results from initial nonrandomized clinical trials, which were primarily designed for safety rather than efficacy, demonstrated a moderate improvement of heart function after stem cell therapy, although most of the beneficial effects were lost during the follow-up period (Wollert et al., 2004) . More recent randomized, placebo-controlled clinical studies involving larger groups of patients suggested small but significant improvements in left ventricular function, although the underlying mechanisms have remained enigmatic (see Povsic and Peterson, 2006 for a recent review).
There is no doubt that homing and tissue integration are prerequisites for a functional benefit of stem/progenitor cell therapies irrespective of the type of cells used and their quality. Any improvement of existing cell-based therapeutic approaches will depend on a better understanding of the interaction of stem cells with the environment that leads to homing and tissue integration. The molecular mechanisms that direct mobilization and homing of bone marrow-derived cells such as MSC, MASC, and EPCs are only partially understood. One of the best-studied examples is the vascular endothelial growth factor and stromal-derived factor-1 loop (VEGF-SDF1 loop), leading to VEGF-dependent mobilization of hematopoietic cells to the blood, which are then ''trapped'' in the close proximity to angiogenic vessels by SDF1, that seems mainly expressed by perivascular myofibroblasts (Grunewald et al., 2006) . Although the identity of circulating cells, which are recruited by the interplay of VEGF and SDF1, has not been fully determined, it is likely that EPCs contribute to this process via the SDF1 receptor CXCR4 since neutralizing antibodies against CXCR4 profoundly inhibited EPC-induced angiogenesis as well as VEGF-and SDF-1-induced migration (Walter et al., 2005) . Likewise, it has been reported that a subset of mesenchymal stem cells strongly express functionally active CXCR4, which promoted migration to bone marrow (Sordi et al., 2005) . Another factor, which has been implicated in the homing of MSCs, is MCP-3, which is transiently upregulated in the infarcted heart after experimental ligation of the coronary artery together with MCP-1/CCL2, MIP-1a, and MIP1b (Schenk et al., 2007) . MCP-3 interacts with CCR1, CCR2, and CCR3, while MCP-1/CCL2 signals via CCR2 (Daugherty et al., 1996) . CCR2 is a G protein-coupled receptor that is activated by MCP-1/CCL2, CCL7, CCL8, CCL12, and CCL13. Activation of intracellular effectors of CCR2 such as adenylate cyclases, PLCßs, PI3Ks, MAPKs, and RhoGEFs occurs mostly via heterotrimeric G-proteins of the G I/O and the G q family (Wong and Fish, 2003) . In addition, Terashima et al. demonstrated that activated CCR2 interacts directly with FROUNT, a unique clathrin heavychain repeat homology protein, which forms clusters at the cell front during chemotaxis. Overexpression of FROUNT enhances signaling via CCR2 in monocytes and stimulates chemotaxis by linking activated CCR2 to the PI(3)K-Rac-lamellipodium protrusion cascade (Terashima et al., 2005) .
We have recently described the isolation of multipotent adult mesenchymal stem cells (MASC) from different organs of mice including the bone marrow. MASCs can be induced to express cell-type specific markers that are characteristic for heart, muscle, brain, and liver cells . After injection into mouse blastocysts, these cells contributed to the development of chimeric embryos in vivo, although functional differentiation into skeletal myotubes occurred via IL-4-dependent fusion with native myotubes and not by cell autonomous differentiation .
Here we show that MASCs rely on the cytokine receptor CCR2 for organ-specific homing. CCR2-mediated activation of stem cells critically depended on the intracellular adaptor molecule FROUNT, which caused polarization of stem cells, resulting in clustering of CCR2 and reorganization of the cytoskeleton.
RESULTS

mBM-MASCs Are Long-Term Self-Renewing Cells that Home to the Bone Marrow of Wild-Type Mice
We have previously devised a protocol for the isolation of multipotent mesenchymal cell populations (mBM-MASCs) from adult murine bone marrow, which show a remarkable developmental plasticity as indicated by the expression of various cell-type specific differentiation markers upon induction . Our protocol (Belema-Bedada and Braun, 2008; Belema-Bedada et al., 2005) MASC-2), which can be propagated for several passages in vitro (>25 passages) without signs of senescence and cellular transformation (i.e., contact inhibition, lack of tumor formation after transplantation into immune-deficient mice). MASCs also participate in embryonic development of chimeric mice after blastocyt injection without causing obvious malformations, although the degree of chimerism is limited . The majority of metaphase spreads of MASCs (12 out of 15 for MASC-1; 9 out of 15 for MASC-2) were euploid and lacked chromosomal aberrations, including translocations as indicated by multicolor FISH analysis ( Figure S1 available online). Similar results have been obtained recently for mouse and human MSCs (Bochkov et al., 2007; Tolar et al., 2007) , which show a certain degree of cytogenetic abnormalities even at low passage numbers, a phenomenon that is also well known for primary ES cultures (Nichols et al., 1990) . It has to be mentioned that the incidental occurrence of aneuploid metaphase spreads might also be caused by preparation artifacts and does not necessarily indicate instability of the karyotype. The expression of various stemness markers in these cells and the ability for self-renewal in vitro prompted the question whether mBM-MASCs competitively repopulate their niche within the bone marrow stroma for an extended time in vivo. A group of 3-month-old ICR mice (n = 5) was injected via the tail vein with 2.5 to 3 3 10 5 of mBM-MASCs1 or mBM-MASCs2 cells suspended in 75 ml PBS and analyzed after 3 months (n = 3) and 6 months (n = 2). In each case, EGFP-positive cells were recovered from the bone marrow showing a similar morphology and similar proliferation properties as parental cells ( Figure 1A ). Essentially the same results were obtained for mBM-MASCs1 and mBMMASCs2. In the course of this study, we collectively refer to both cell populations as mBM-MASCs unless differences between both populations were noted. To further prove the origin of EGFP-positive cells, we confirmed the expression of EGFP in isolated cells by RT-PCR ( Figure 1B ). The number of EGFPpositive cells within the bone marrow, which were derived from injected cells, was relatively low in the competitive stromal environment. Immunostaining for EGFP expression of cells isolated from the bone marrow and FACS analysis of EGFP autofluorescence revealed that <1% of lin À bone marrow cells originated from injected cells both 3 and 6 months after transplantation ( Figure 1A and data not shown (Weissman, 2000) . To investigate whether mBMMASCs, which had been maintained for several months in a recipient host and exposed to two rounds of isolation and cultivation, were still able to populate the bone marrow of recipient mice, EGFP-positive cells were transplanted into a secondary host. mBM-MASCs were readily isolated from the bone marrow of secondary host with roughly the same efficiency as from the primary recipient (Figure 1 ). Isolated cells also maintained their ability to respond to inductive cues by expression of cell typespecific markers (data not shown) . Interestingly, we were unable to locate EGFP-positive cells in other organs of primary and secondary hosts including liver, heart, skeletal muscle, brain, and spleen 3 months after transplantation, indicating tissue-specific homing of injected cells.
Identification of Potential Homing Receptors of mBM-MASCs
The restricted tissue distribution of EGFP-labeled mBM-MASCs in recipient mice indicated the presence of a specific homing mechanism that guided transplanted cells into the bone marrow after transplantation. Since directed homing and tissue integration might be the key to an improvement of existing therapeutic applications of stem cells irrespective of their mode of action, we wanted to learn more about the molecule that mediated homing of mBM-MASCs. We therefore decided to investigate the expression of potential homing receptors in mBM-MASCs by DNA microarray analysis. Probe sets from all groups were characterized according to gene ontology (GO) annotation (Ashburner et al., 2000) to identify cell surface receptors expressed by mBM-MASCs. Figure S2 depicts a selection of chemokine receptors and other ligand-activated receptors that have been implicated in homing and migration. We detected the presence of the cytokine receptors CCR2 and CCR10 in mBM-MASCs. CCR2 and CCR10 have both been implicated in homing and migration of various different cell types, including mesenchymal stem cells (Spring et al., 2005) . Furthermore, mBM-MASCs expressed a number of other receptors that have been shown to contribute to cellular migration and homing including c-met and Fgf receptors (Neuhaus et al., 2003) . The expression of CCR2, CCR10, Tgfbr1, Tgfbr2, Pdgfra, Pdgfrb, Il6st, Fgfr1, and Fgfr2 was further confirmed by RT-PCR analysis ( Figure S3 ). Immunofluorescence staining revealed that most, but not all, mBM-MASCs express CCR2 ( Figure S4 ). CCR2 expression was also found in human mesenchymal stem cells and in C2C12 myoblasts ( Figure S4 ). mBM-MASCs did also express high amounts of CXCL12 (SDF-1), which had been implicated with the trafficking of bone marrow-derived circulating cells (Grunewald et al., 2006) and moderate amounts of CXCR3, CXCR4, and CXCR6 ( Figure S2 and data not shown).
MCP-1 and HGF/SF Strongly Stimulate Migration of mBM-MASCs In Vitro
The expression of putative homing receptors does not necessarily prove their ability to guide cells to specific targets. We therefore analyzed the ability of several ligands of putative homing receptors to induce targeted migration of mBM-MASCs in vitro in a modified Boyden microchemotaxis chamber system (Figure 2A) . Both mBM-MASCs1 and -2 showed random migration in the absence of ligands, although this activity was relatively low compared to the addition of chemoattractants ( Figure 2B ). Most of the 19 factors had been reported to elicit migration of various different cell types. Therefore, it was no surprise that all 19 factors stimulated targeted migration of mBM-MASCs, at least to a certain degree (Figure 2 ). The response of mBMMASCs to different cytokines followed a bell-shaped concentration response curve with the exception of Eotaxin and PDGF-AB ( Figure S5 and data not shown). A strong response was caused by MCP-1 and HGF/SF, which signal via CCR2 or CCR4 and mBM-MASCs1 (A) and -2 (B) were exposed to different cytokines and growth factors in a Boyden microchemotaxis chamber assay to identify potential chemoattractants. Cells, which had migrated toward the source of chemoatractants (lower chamber) by passing through a membrane filter, were quantified using the ImageJ software. Concentration of cytokines used was as follows: PDGF-AA, 20 ng/ml; PDGF-AB, 20 ng/ml; NAP-2, 5ng/ml; MIP-4, 10 ng/ml, Eotaxin, 10 ng/ml; M-CSF, 20 ng/ml; TNF-a, 10 ng/ml; TGF-b, 10 ng/ml; MCP-1, 50 ng/ml; MCP-4, 800 ng/ml; MIP-2a, 5 ng/ml; OSM, 40 ng/ml; IL-8, 100 ng/ml; MIP-3a, 100 ng/ml; Lymphotactin, 100 ng/ml; FGF-acidic, 20 ng/ml; HGF, 30 ng/ml; IGF-1, 100 ng/ml; FGF-basic, 30 ng/ml. Data represent mean ± SD (n = 4). Representative examples of MCP-1 stimulated migration of mBMMASCs1 and -2 after staining with Hoechst33258 (C).
c-met, respectively. No principal difference between the migratory activity of mBM-MASCs1 and -2 were noted. Both populations, which differ in the expression of CD34 and Sca1 (MASCs1 are CD34 À /Sca-1 high ; MASCs2 are CD34 + /Sca-1 moderate ) showed a similar response pattern with only minor differences concerning the reaction to PDGF-AA, PDGF-AB, NAP-2, and FGF-1 (Figures 2A and 2B) . We also detected a strong chemoattractive activity of VEGF and SDF1 ( Figure S5 ). The pronounced stimulation of migration by MCP-1 suggested that the CCR2 receptor, which we found to be expressed in mBM-MASCs, might be instrumental for targeted migration and homing of these cells.
Directed Expression of MCP-1 in the Myocardium of Transgenic Mice Mobilizes mBM-MASCs and Leads to Specific Homing into the Heart
To probe the physiological relevance of MCP-1-mediated homing processes in vivo and to address directly the ability of MCP-1 to guide mBM-MASCs into individual organs, we utilized a transgenic model in which MCP-1 is specifically expressed in the myocardium (Kolattukudy et al., 1998) . Genetically labeled mBMMASCs1 and -2 (3 3 10 5 ) were injected intravenously into 12-to 16-week-old MyHC-MCP-1 and control mice (n = 12) (Martire et al., 2003) . Injected animals were sacrificed after 7 and 14 days, and tissue samples were processed for immunofluorescence staining using an antibody against EGFP. Engraftment of EGFP-expressing cells was clearly visible in hearts of MCP-1 transgenic mice (Figures 3Ag-3Ai ), but not in wild-type control mice. Virtually every microscopic field in hearts of transgenic mice contained numerous EGFP-expressing cells, which either formed large clusters of cells (Figures 3Ag-3Ai ) or were scattered within the myocardium (Figures 3Ba-3Bd) . Occasionally, we also found EGFP-labeled, mBM-MASCs1-and -2-derived cells in the liver and in the spleen of MCP-1 transgenic mice, although the amount of such cells was much lower in these tissues, and most sections did not contain EGFP-expressing cells (Figures  3Aa-3Af) . A quantitative assessment of the number of MASCs in different organs revealed that hearts of MyHC-MCP-1 mice contained 20.70 ± 1.7 cells/microscopic field in comparison to 0.9 ± 0.7 in skeletal muscle, 0.8 ± 0.4 in the brain, and 1.6 ± 0.9 in the liver (n = 6) ( Figure S6A ). In an additional attempt to quantify homing and engraftment of transplanted mBM-MASCs in different tissues and to avoid potential staining artifacts, we performed real-time RT-PCR analysis of whole organs (Figure 4) . Only a low expression of EGFP-RNA was found in skeletal muscle, brain, and kidney reflecting the low number of of mBMMASCs-derived cells in these tissues (Figures 3 and 4) . In the heart, a strong expression of EGFP was detected, which was eight times higher than in the liver or the spleen, indicating that mBM-MASCs-derived cells predominantly homed and engrafted into the heart (Figure 4) . Clearly, the homing of mBM-MASCsderived cells into the heart was dependent on the expression of MCP-1 since no significant amounts of EGFP mRNA were detected in the hearts of wild-type control animals (data not shown).
It has been proposed that VEGF induces expression of SDF-1 in activated perivascular myofibroblasts leading to an entrapment of circulating bone marrow-derived cells in the vicinity of growing vessels (Grunewald et al., 2006) . To analyze the expression of SDF-1 in vivo by engrafted EGFP-expressing cells, double-labeling with EGFP and SDF-1 antibodies were performed. mBM-MASCs, which had homed into the hearts of MCP-1 transgenic mice after intravenous administration, were strongly positive for SDF-1 irrespective of whether these cells formed clusters of cells (Figures 3Ba-3Bc ) or were scattered within the myocardium (Figures 3Bd-3Bf) . We also detected additional SDF-1-positive cells in the vicinity of engrafted , and heart (g-i) 14 days later and stained with an antibody against EGFP. EGFP-labeled cells were occasionally detected in some sections from liver (a-c) and spleen (d-f), while virtually all sections derived from the heart (g-i) contained large numbers of mBM-MASCs-eGFP cells. (B) mBM-MASCs that have engrafted into the heart strongly express SDF-1. Sections were reacted with antibodies against EGFP (a and d) and SDF-1 (b and e). Merged images of (a) and (b) and of (d) and (e) are shown in (c) and (f), respectively. mBM-MASCs (Figure 3Bc, inlet) , indicating that other cells responded to the release of SDF-1 or were recruited by the engrafted cell population.
Organ-Specific Homing of mBM-MASCs Depends on FROUNT, a Clathrin Heavy-Chain Repeat Homology Protein
The cellular mechanisms that cause homing of stem cells are only barely understood. To begin to decipher the machinery that transmits chemotactic homing signals within stem cells and to prove a decisive function of CCR2-mediated receptor signaling, we decided to interfere with the function of FROUNT. FROUNT links activated CCR2 to the PI(3)K-Rac-lamellipodium protrusion cascade and stimulates chemotaxis of macrophages (Terashima et al., 2005) . Full-length FROUNT or a truncated version, which contains a preserved CCR2-binding domain that competes with endogenous FROUNT in CCR2 binding and, thus, serves as a dominant-negative effector, were cloned together with an IRES-EGFP cassette into a lentiviral expression vector (Lois et al., 2002) and were subsequently used to infect mBM-MASCs. Infected cells were enriched by FACS sorting (EPICS ELITE ESP; Beckman Coulter) through gating for EGFP-expressing cells resulting in homogenous cell populations (>95% infected). Western blot analysis revealed that expression of DN-FROUNT in mBMMASCs did not alter the expression level of CCR2 ( Figure S7 ). Surprisingly, overexpression of active FROUNT led to a rapid loss of the stem character of mBM-MASCs and was, therefore, excluded from further analysis (data not shown).
We first tested the ability of DN-FROUNT to interfere with MCP-1-mediated targeted migration of mBMMASCs in vitro in the modified Boyden chamber assay. Expression of DN-FROUNT efficiently blocked MCP-1 mediated targeted migration while it had no effect on the migratory activity caused by HGF, VEGF, SDF1, or a combination of VEGF and SDF1 ( Figure 4A and Figure S5 ). To verify that the effect of MCP-1 was mediated directly via binding to CCR2, we examined the effects of neutralizing CCR2-antibodies on the migration of mBMMASCs. As shown in Figure 4A , MCP-1-stimulated migration of mBM-MASCs was strongly inhibited by CCR2-antibodies (20 ng/ml), while no significant inhibition of HGF-stimulated migration was observed.
Next, we wanted to investigate whether inhibition of FROUNT also blocks homing of transplanted mBM-MASCs in vivo. DN-FROUNT-infected cells and cells infected with an EGFP-control virus were injected into the tail vein of transgenic MCP-1 mice (n = 6 for each cell preparation). Injected animals were sacrificed after 14 days, and tissue samples were processed for immunofluorescence staining using an antibody against eGFP and for RT-PCR analysis. A low engraftment of DN-FROUNT-infected cells was found by EGFP-antibody staining in the heart (0.8 ± 0.6 cells/microscopic field) and in other organs of MCP-1 transgenic mice (0.4 ± 0.5 in skeletal muscle, 0.3 ± 0.4 in brain, and 1.5 ± 0.5 in the liver [n = 6]) ( Figure S6A ), while mBM-MASCs infected with the EGFP-control virus were present in the hearts of MCP-1 transgenic mice at the same rate as in the previous experimental series (Figure 3 ; Figure S6A ). Likewise, we measured a strong expression of EGFP-mRNA by real-time RT-PCR in the hearts of MCP-1 mice, which had been infected with the EGFP-control virus, but not in mice, which received cells infected with the DN-FROUNT-IRES-EGFP virus ( Figure 4B, C) . We concluded that blocking of FROUNT function abolished organ-specific homing of mBMMASCs in vivo.
FROUNT-Mediated Signaling Is Instrumental for Homing of mBM-MASCs to Hearts Damaged by Ischemia/Reperfusion
We next wanted to know whether mBM-MASCS home to the injured heart in a disease model that does not rely on overexpression of MCP-1 and whether such a type of homing would also depend on the CCR2-FROUNT axis. We therefore injected 3 3 10 5 genetically labeled mBM-MASCs1 and -2 intravenously into 12-to 16-week-old ICR mice (n = 5) that had been undergone ischemia/reperfusion of the myocardium by transient ligation of the LAD for 90 min. This procedure results in the formation of scar tissue devoid of cardiomyocytes and formation of a border zone (BZ) characterized by enhanced deposition of collagen-3. The remote zone (RZ) is further apart from the infarct area and is characterized by the normal presence of cardiomyocytes and no enhanced collagen depositions ( Figure S8 ). Immunofluorescence-based analysis of injected animals 7 days after transient LAD ligation and injection of cells revealed the presence of numerous eGFP-labeled MASCs in the BZ ( Figures 5A-5C ), while comparatively few labeled cells were detected in the RZ (Figures 5D-5F ). A quantitative assessment of the number of MASCs showed 28.81 ± 1.75 cells/microscopic field in the BZ in comparison to 3.6 ± 1.57 cells /microscopic field in the RZ (n = 5) ( Figure S6B ). Next, we investigated whether inhibition of FROUNT blocks homing of transplanted mBM-MASCs to the damaged myocardium. DN-FROUNT-infected cells were injected into the tail veins of ischemically damaged mice (n = 6). Injected animals were sacrificed after 7 days and analyzed as described above (Figures 5J-5L ). We found a strong decrease of engraftment of DN-FROUNT-infected cells in the BZ (2.2 ± 0.75 cells/microscopic field) and also in the RZ (0.33 ± 0.28 cells/microscopic field) ( Figure S6B ). We concluded that blocking of FROUNT function strongly inhibited recruitment of mBM-MASCs to ischemically damaged myocardium.
FROUNT Is Instrumental for Clustering of CCR2 and for Reorganization of the Cytoskeleton in MASCs
To learn more about the processes that control targeted migration and homing of mBM-MASCs, we analyzed the subcellular distribution of CCR2 and FROUNT in MCP-1/CLL2 stimulated cells by immunofluorescence staining and laserscan microscopy. In all experiments, mBM-MASCs were used that had either been infected with an EGFP control virus or a virus expressing DN-FROUNT-IRES-EGFP. Infected cells were sorted by FACS to generate homogenous cell populations (>95% infected). In the absence of MCP-1, CCR2 was mainly confined to the plasma membrane resulting in a diffuse cellular staining ( Figure 6A ), although some cells showed a perinuclear accumulation of CCR2 (inlet in Figure 6A ). FROUNT was either localized within the cytoplasm or at a perinuclear position in unstimulated mBM-MASCs ( Figure 6B ). The latter localization would also concur with the proposed function of FROUNT/Nup85 as a part of the nuclear pore complex (Cronshaw et al., 2002) . Stimulation of mBM-MASCs by MCP-1 resulted in clustering of CCR2 within the plasma membrane ( Figure 6C) . Interestingly, the accumulation of CCR2 occurred always on one side of the nucleus, indicating polarization of the cells, although MCP-1 was not applied in a vectored manner (Figure 6 ; Figure S9 ). The relocalization of FROUNT followed a similar pattern. Again, the accumulation and clustering of FROUNT usually occurred at one side of the nucleus with only rare exceptions (Figure 6D , inlet; Figure S9 ). Expression of a dominant-negative version of FROUNT that carried only the C-terminal, CCR2-binding domain of FROUNT efficiently inhibited clustering of CCR2 and FROUNT, as well as the polarization of mBM-MASCs ( Figures 6E and 6F) . Prevention of CCR2 activation by dominant-negative FROUNT leads to predominant cytoplasmic localization of CCR2 ( Figure 6E ), while FROUNT was detected in granules and in the cytoplasm ( Figure 6F ). Similar staining patterns were observed during directed migration in a Boyden chamber assay when mBMMASCs were induced by MCP-1 to migrate through a filter with 10 mm pore sizes (data not shown).
Directional sensing and polarization has to be transmitted to the migratory apparatus of a cell in order to achieve targeted Genetically labeled mBM-MASCs-eGFP were intravenously injected into mice, which had been subjected to ischemia/reperfusion for 90 min. Immunofluorescence staining of sections covering the scar, the border zone (A-C), and the remote zone (RZ) (D-F) 7 days after ischemia/ reperfusion is shown. Sections were reacted with antibodies against EGFP and counterstained with DAPI. Only few injected cells were present in the RZ (D-F) compared to the BZ (A-C). Presence of intravenously injected eGFP-labeled cells infected with a control retrovirus (G-I) and infected with a retrovirus expressing DN-FROUNT (J-L) 7 days after ischemia/ reperfusion in the BZ is shown. movement and homing. Previous findings suggested that targeted movement of cells goes along with the formation of actin-filled projections (Devreotes and Janetopoulos, 2003) . We therefore visualized the distribution of F-actin in MCP-1-stimulated cells by phalloidin staining and assessed the formation of pseudopodia in mBM-MASCs (Figure 7) . We detected localized formation of actin filaments either in lamellipodia protrusions (arrows in Figure 7A ) or at other discrete domains (inlet in Figure 7A ) that were usually localized at one side of the nucleus. Infection of MCP-1 stimulated cells with a retrovirus encoding DN-FROUNT completely abrogated this process and resulted in occurrence of stress fiber-like actin filaments ( Figure 7B ). The formation of lamellipodia protrusions was efficiently inhibited in these cells ( Figure 7B) . Similarly, pretreatment of mBM-MASCs with the PI(3)K inhibitor Wortmannin before application of MCP-1 diminished the formation of lamellipodia protrusions ( Figure 7C ). The combined treatment with DN-FROUNT and Wortmannin did not result in a synergistic inhibition of lamellipodia protrusions suggesting that FROUNT and PI(3)K did act in the same pathway. Most likely, activated CCR2 results in accumulation of PIP3 by PI(3)K in a FROUNT-dependent manner to promote targeted migration of mBM-MASCs.
DISCUSSION
In this study, we have analyzed some of the cellular events that lead to homing and tissue engraftment of intravenously injected mBM-MASCs. Due to the therapeutic potential of mesenchymal stem cells and related cell populations, several attempts have been made recently to identify molecules that might promote tissue-specific homing, although the receptors and cellular processes that mediate such response have been largely neglected. In a comprehensive survey of potential chemoattractants, Ozaki and colleagues detected a strong chemotactic effect of PDGF-BB on mesenchymal stem cells (MSCs) in vitro, although other factors such as EGF and HGF also stimulated migration (Ozaki et al., 2007) . In our assay system, the effects of PDGFs were less pronounced, which might be explained by differences between MSCs and mBM-MASCs. In a recent study, Schenk et al. demonstrated enhanced homing of MSCs into infarcted hearts that had been engineered by injection of cardiac fibroblasts expressing MCP-3 into the infarct border zone (Schenk et al., 2007) . Although the effects of MCP-3, which signals via CCR1, CCR2, and CCR3, were significant, it seems difficult to separate the effects of MCP-3 expression from the consequences of tissue damage and hypoxia imposed by infarction. We have resorted to a transgenic system designed to activate the CCR2 receptor in vivo to prove that CCR2-mediated mobilization and homing of mBM-MASCs is sufficient to direct cells into a specific organ. Our focus was on events 7 and 14 days after administration of mBM-MASCs, which makes sure that we do not monitor transient interactions of incoming cells with recipient organs but veritable homing and engraftment processes. The transgenic expression of MCP-1 in the heart seems to guarantee that we primarily analyze effects of this cytokine and not effects that are imposed by external damages. Nevertheless, one has to consider that extended expression of MCP-1 in the heart does also trigger secondary processes (Kolattukudy et al., 1998) , although we have used MCP-1 transgenic animals at an age in which they had not yet encountered major pathological changes in the heart (Martire et al., 2003) . Clearly, distinct conditions within the myocardium are required to attract significant numbers of transplanted mBM-MASCs. Interestingly, we did not find a preferential accumulation of mBMMASCs in hearts of desmin knockout mice suffering from severe cardiomyopathy (Milner et al., 1999 ) (data not shown), while a strong engraftment of mBM-MASCs was detected in the BZ of hearts damaged by ischemia/reperfusion, which reached (at least locally in the BZ) similar levels as in hearts of MCP-1 transgenic animals. Intriguingly, both models (ischemia/reperfusion and MCP-1 overexpression) are characterized by a high degree of mononuclear cell infiltration and inflammatory reactions, which might explain why mBM-MASCs were efficiently attracted by a cytokine that has been thought to be primarily involved in the attraction of macrophages. The ischemia/reperfusion model does also demonstrate the physiological relevance of MCP-1 FROUNT-mediated clustering of CCR2 for the control of homing of mBM-MASCs into diseased organs.
Our study does not address the question whether and how mBM-MASCs might improve local repair processes, yet some implications for the therapeutic application of stem cells are apparent. Clearly, stimulation of the CCR2/FROUNT/PI(3)K signal transduction pathway might help to summon different populations of mesenchymal stem cells to the heart or to other tissues in order to contribute to tissue remodeling and to aid recruitment of additional cells. As a caveat, one has to be aware that the CCR2/FROUNT/PI(3)K cascade is not unique to stem cells. Monocytes chemoattractant proteins (MCPs) and their receptors play pivotal roles in the development of inflammatory responses and are crucial for the transmigration of immune cells to sites of inflammation. CCR2 is a major receptor for MCP-1 (CCL2) and other MCPs, including CCL8 (MCP-2) and CCL7 (MCP-3) (Charo and Peters, 2003) . Because CCR2 regulates monocytes and macrophage recruitment and is necessary for macrophage-dependent inflammatory responses, it has been proposed that inhibition of FROUNT might be used to fight various chronic inflammatory immune diseases by preventing infiltration of tissues by macrophages (Terashima et al., 2005) . Our results suggest that such an approach will most certainly also block homing of mesenchymal stem cells, which seem to modulate inflammatory response and improve repair processes (Schenk et al., 2007) . Along the same line: a simple enhancement of tissue engraftment of mesenchymal stem cell by overexpression or injection of single chemoattractants will most likely lead to engraftment of multiple cell types, including inflammatory cells, which might cause an enhanced inflammatory reaction thereby interfering with tissue repair.
It seems unlikely that homing of circulating cells depends on a single molecule or pathway. Therefore, it was interesting to note that expression of dominant-negative FROUNT did abrogate homing of mBM-MASCs into myocardium damaged by ischemia/reperfusion, thereby indicating that FROUNT-mediated migratory processes are pivotal for the recruitment of mBM-MASCs into the ischemically damaged heart. Apparently, FROUNT-mediated signaling is a limiting step in the homing process that cannot be easily replaced or bypassed by other signaling events independent of the complex nature of regulatory mechanisms that ascertain recruitment of circulatory cells.
We have also shown that engrafted mBM-MASC express SDF-1 and also stimulate accumulation of SDF-1-positive cells in their vicinity. The expression of SDF-1 by mBM-MASCs that have engrafted into a recipient tissue might therefore initiate an additional regulatory circuit that leads to the entrapment of circulating cells. Based on our findings, we propose the following model for CCR2/FRONT-mediated homing of mBM-MASCs ( Figure S10 ). Before stimulation of mBM-MASCs, CCR2 and FROUNT are evenly distributed within the cytoplasm or at a perinuclear localization. Binding of MCP-1 to CCR2 activates the receptor and recruits FROUNT, resulting in the formation of clusters of CCR2 and FROUNT at the plasma membrane. The formation of clusters of CCR2 and FROUNT goes along with the polarization of cells as indicated by the asymmetric distribution of CCR2/FROUNT clusters at either side of the nucleus. The association of FROUNT with CCR2 leads to activation of PI(3)K, which results in localized formation of actin filaments and lamellipodia protrusions. In principle, our model is compatible with the idea of ''local excitation, global inhibition,'' which explains why cells respond to changes in receptor occupancy and adapt when occupancy is held constant (Devreotes and Janetopoulos, 2003) . The strong polarization of mBM-MASCs, which occurred even when the chemoattractant was not supplied as a gradient, might only be explained by a strong ''positive feedback loop'' that selectively amplifies a signal at specific sites of the cell and, therefore, localizes the response (Meinhardt, 1999) . The recruitment of FROUNT to the activated CCR2 receptor seems to be an important component of this loop since DN-FROUNT prevented localized responses and cell polarization. At present, it remains unclear whether the profound changes in proliferation characteristics and cellular morphology of mBM-MASCs after FROUNT overexpression were caused by activation of the FROUNT/PI(3)K-Rac pathway or whether additional signaling cascades were initiated. Further research will be necessary to solve this question.
EXPERIMENTAL PROCEDURES
RNA Isolation, RT-PCR, Quantitative Real-Time RT-PCR, and Western Blot Analysis RNA isolation, reverse transcription-PCR (RT-PCR), and quantitative real-time PCR analyses were performed as described previously (Ebelt et al., 2007) . Detailed protocols and primer sequences are available on request. The homing index of mBM-MASCs-eGFP and mBM-MASCs-DNF was displayed as the ratio of the normalized expression of EGFP to a reference transcript (GAPDH). Relative expression levels under different experimental conditions were compared based on the expression level of the gene of interest. Western blot analysis was performed as described (Ebelt et al., 2007) .
Microarray Analysis RNA was isolated from undifferentiated mBM-MASCs1 and -2 and hybridized onto GeneChip Mouse Genome 430 2.0 Array (Affymetrix). Each cell line was represented by three biological replicates. GeneChip hybridization and biotinylated cRNA detection were done according to standard Affymetrix protocols. The raw data were processed by the robust multiarray average (RMA) method (Irizarry et al., 2003) .
Construction of Recombinant Lentiviruses and Infection of mBM-MASCs
Full-length FROUNT and dominant-negative (DN)-FROUNT cDNAs (Terashima et al., 2005) were cloned into the c-FUW lentivirus transfer vector (Lois et al., 2002) . All constructs were verified by sequence analysis. mBMMASCs were subjected to FACS to separate infected from noninfected cells using the EPICS ELITE ESP cell sorter (Beckman Coulter).
Immunofluorescence Staining eGFP-labeled mBM-MASCs were visualized using a polyclonal rabbit antieGFP primary antibody and Alexa594 anti-rabbit secondary antibody (Molecular Probe). Goat polyclonal antibodies directed against FROUNT also known as Nup85 (mouse) and Nup75 (human) were purchased from Santa Cruz. A rabbit monoclonal antibody to CCR2 was obtained from Abcam. The secondary detection system was biotinylated anti-mouse or anti-rabbit IgG (Biotrend) conjugated with Cy-2, Cy-3, or Cy-5. Nuclei were stained with TOTO-3, Draq5 (Molecular Probes), and Hoechst 33258 (Dako). The samples were examined with confocal scanning laser microscopes Leica TCSNT and Leica TCS SP2SE as described (Kostin et al., 2003) .
Engrafted cells in different organs were counted per microscopic field (magnification 2003) from 400 microscopic fields randomly selected from 40 sections (10 fields/section) from each organ and animal (n = 6 for MyHC-MCP-1 mice). Mice damaged by ischemia/reperfusion were analyzed using the same approach, but in this case, 150 randomly chosen microscopic fields from 15 sections (10 fields/section) were counted (n = 5). Mean values and SD were calculated using the total number of cells from each organ and animal.
In Vitro Migration Assay Migration assays were performed in a chemotaxis chamber as described previously (Neuhaus et al., 2003) . Migration assays were performed by adding serum-free DMEM supplemented with individual chemoattractants (concentration range between 0.1 and 1000 ng/ml) into the lower chemotaxis chamber. The upper chemotaxis chamber was loaded with 25,000 cells in DMEM low glucose. Cells that which had migrated toward the lower chamber were visualized by Hoechst 33258 (Dako) staining. The migration index was calculated based on the ratio of cells that migrated in response to chemoattractants to cells that migrated randomly in absence of chemoattractants. The ratio resulting from random migration was set to zero. The area occupied by labeled nuclei was quantified using the ImageJ software.
Cell Culture and Tail Vein Injection of Mice mBM-MASCs from male ICR mice were derived as described previously (Belema-Bedada and Braun, 2008; Belema-Bedada et al., 2005) . This isolation procedure is mainly based on two enrichment steps: (1) differential adherence of cells to the surface of tissue culture dishes and (2) slow growth under adverse culture conditions with low growth factor concentrations (''attrition'').
For experiments, freshly isolated individual clones were used at low passage numbers (<25) after phenotyping by FACS analysis. Descendants of transplanted, EGFP-labeled mBM-MASCs were isolated from the bone marrow using the same procedure, but employing EGFP-based FACS as the last purification step. EGFP expression was directed by integrated EGFP-encoding lentiviruses. Cells were karyotyped by ''color karyotyping'' (mFISH) as described (Liyanage et al., 1996) .
The long-term renewing capacity of mBM-MASCs was assessed by serial transplantation of mBM-MASCs into the tail vein and (re)isolation from the bone marrow. The generation of MyHC-MCP-1 mice has been described previously (Kolattukudy et al., 1998) . For tail vein injection, 2.5 to 3 3 10 5 cells suspended in 75 ml PBS were injected into tail veins of 12-to 16-week-old MyHC-MCP-1 and control mice (Martire et al., 2003) . Adult female ICR mice underwent ischemia/ reperfusion following the same procedure as described before for permanent LAD ligations (Ebelt et al., 2007) , but with opening the ligature after 90 min.
SUPPLEMENTAL DATA
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